Mourabit Halima, Author at MediaMedic

CCHIO 2024 | Dr. Gang Ding: The Era of “Integration” — Exploring Tumor Rehabilitation and Health Education for a China-Specific Oncology Prevention

By Mourabit Halima 2024.12.11

The 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO) concluded successfully on November 17. Following the strategic framework of "collaborative integration" in disciplinary development, the conference established dedicated sessions on tumor rehabilitation, health education, cancer prevention, and screening. These sessions offered comprehensive and multidimensional insights into new perspectives, technologies, and concepts for the full-cycle management of oncology, spanning prevention, screening, diagnosis, treatment, and rehabilitation.

Dr. Zhaochong Zeng: Advancing Liver Cancer Care with Targeted Radiotherapy Strategies and Dual MDT Approaches

By Mourabit Halima 2024.12.11

China bears a significant burden of liver cancer. To prevent its onset and progression, the country, society, and countless physicians have undertaken extensive measures under the framework of "three-level prevention," achieving remarkable progress. With the increasing proportion of early diagnosis and treatment of liver cancer in recent years, a key focus for radiotherapy specialists has been how to precisely select appropriate radiotherapy methods for early-stage liver cancer patients to improve their prognosis. Oncology Frontier interviewed Dr. Zhaochong Zeng from Zhongshan Hospital, Fudan University, to discuss liver cancer prevention and control in China, explore strategies and advantages of proton therapy, brachytherapy, and combined radiotherapy with interventional treatments for early-stage liver cancer, and outline the role of the radiotherapy department in multidisciplinary team (MDT) development for liver cancer.

CCHIO 2024 | Dr. Hong Liu: New Perspectives on Breast Cancer Rehabilitation – The Importance of Psychological Well-being and Multidisciplinary

By Mourabit Halima 2024.12.11

Breast cancer not only threatens patients' lives but also imposes a heavy psychological burden on women. As the number of breast cancer cases continues to rise, its rehabilitation is gaining increasing attention from society. How to effectively promote comprehensive recovery for breast cancer patients has become an important issue in the medical field. During the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO), Oncology Frontier interviewed Dr. Hong Liu, Chair of the Breast Cancer Integrated Rehabilitation Committee of the Chinese Anti-Cancer Association and a leading expert at Tianjin Medical University Cancer Institute and Hospital. Professor Liu discussed the importance of psychological rehabilitation for breast cancer patients, prospects for the development of the rehabilitation field, applications of new technologies and methods, and the significance of multidisciplinary collaboration. Drawing on her extensive clinical experience, Professor Liu shed light on new trends in breast cancer rehabilitation, offering hope for patients.

The 66th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA, from December 7th to 10th, 2024

By Mourabit Halima 2024.12.10

The 66th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA, from December 7th to 10th, 2024. As one of the most influential platforms for scientific communication in hematology, this global event attracted over 25,000 professionals, including clinicians, researchers, and healthcare leaders from more than 100 countries. The conference covered all aspects of malignant and non-malignant hematology, from cutting-edge research to clinical practice and therapeutic innovation, reflecting the latest advancements and future trends in the field.

AASLD 2024丨Dr. Jie Li and Dr. Li Zhu: PRO-C3 and GP73 Combined Non-Invasive Fibrosis Score Wins Poster of Distinction

By Mourabit Halima 2024.12.10

During the 2024 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), a research team led by Dr. Jie Li from Nanjing Drum Tower Hospital, Nanjing…

The 66th American Society of Hematology Annual Meeting (ASH)

By Mourabit Halima 2024.12.10

The 66th American Society of Hematology Annual Meeting (ASH) was grandly held in San Diego, USA, from December 7th to 10th, 2024. This annual event is one of the most influential scientific communication platforms in the field of hematology worldwide. This edition of the ASH Annual Meeting attracted over 25,000 professionals, including clinicians, scientists, researchers, and healthcare decision-makers from more than 100 countries around the globe. The conference covered all aspects of malignant and non-malignant hematology, from basic scientific research to clinical practice, from drug development to therapeutic innovation, reflecting the latest advancements and future trends in the field of hematology.

The 8th West China Uro-Oncology Tianfu Academic Conference丨Dr. Yige Bao: Perioperative Personalized Treatment of UTUC Based on ADC Drugs and the West

By Mourabit Halima 2024.12.10

Upper tract urothelial carcinoma (UTUC), encompassing renal pelvic and ureteral cancers, is relatively rare, with unique characteristics in the Chinese population, such as distinct disease features and molecular biology profiles. The 8th West China Uro-Oncology Tianfu Academic Conference, recently held in Chengdu, provided a platform to discuss how to better address the challenges in UTUC treatment and improve patient outcomes. In this event, Oncology Frontier interviewed Dr. Yige Bao from West China Hospital of Sichuan University, who shared insights into personalized perioperative treatment of UTUC with ADC drugs and the hospital's clinical experiences.

CCHIO 2024丨Dr. Gang Zhu: Enhancing Patient Rehabilitation Concepts and Individualized Treatment for Multistage Benefits in Prostate Cancer Patients

By Mourabit Halima 2024.12.10

With economic development, lifestyle changes, and environmental factors, prostate cancer incidence in China has significantly increased. Screening high-risk populations and providing precision treatment and rehabilitation support based on patient characteristics are crucial for improving cure rates and quality of life. At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), Dr. Gang Zhu, Chair of the Urological Oncology Rehabilitation Committee of the Chinese Anti-Cancer Association and Director of General Surgery and Urology at United Family Healthcare, presented insights on individualized treatment for prostate cancer. Urology Frontier had the opportunity to delve deeper into this topic with Professor Zhu.

An Exploratory Analysis of the PRESERVE 1Trial: Assessing Trilaciclib’s Role in Reducing Chemotherapy-Related Toxicity in Metastatic Colorectal Cancer

By Mourabit Halima 2024.12.10

On November 23rd, Dr. Tianshu Liu's team from Zhongshan Hospital published a study titled "Trilaciclib prior to FOLFOXIRI/bevacizumab for patients with untreated metastatic colorectal cancer: phase 3 PRESERVE 1 trial" in JNCI Cancer Spectrum(IF=3.4). The PRESERVE 1 trial sheds light on trilaciclib's potential to reduce chemotherapy-related toxicity in mCRC. While its efficacy in mitigating myelosuppression is evident, the antitumor results are concerning. Further studies are needed to explore the balance between toxicity reduction and efficacy, and to determine trilaciclib's optimal use in cancer treatment.

CCHIO 2024 | Dr. Bicheng Zhang: Post-Resistance Strategies for Third-Generation EGFR-TKIs in NSCLC

By Mourabit Halima 2024.12.09

EGFR mutations are among the most common genetic abnormalities in non-squamous non-small cell lung cancer (NSCLC), and EGFR-TKIs have become the standard first-line treatment for advanced EGFR-mutant NSCLC. Despite significant advancements across three generations of EGFR-TKIs, resistance remains unavoidable. Post-resistance treatment options for EGFR-TKI patients, particularly those facing complex third-generation resistance mechanisms, are limited.